MDxHealth initiated with a Buy at Lake Street

Lake Street initiated coverage of MDxHealth (MDXH) with a Buy rating and $7 price target Following the acquisition of the GPS assay from Exact Sciences (EXAS) and the additions of a hereditary prostate cancer test and Resolve mdx, the company now offers a broad array of assays to the urology/uropathology community, the analyst tells investors. The firm believes Street revenue expectations for 2025 are “low and not indicative of the growth opportunity available to mdxhealth” and notes that shares are down 48% year-to-date, driven down by financing overhang, limited market liquidity, and a somewhat negative sentiment toward the broader diagnostics space. This has created “a meaningful buying opportunity for investors,” the analyst contends.